Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
292 participants
INTERVENTIONAL
2023-04-03
2024-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Is it feasible for families to call an interpreter themselves? Will allowing families to call an interpreter themselves increase the rate of professional interpreter utilization?
Participants will be given an interpreting tablet and instructed to use the interpreter application whenever they would like to talk to the medical team. There will be a short survey on the feasibility and acceptability of the intervention for the patients and the medical team. The study team will then look at interpreter use rates before and after the intervention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy of Nurse-driven, Protocol Guided Ventilator Weaning in a Medical-Surgical Intensive Care Unit (ICU)
NCT00786617
Mobile App to Promote Family Caregiver Engagement in the Intensive Care Unit
NCT05157919
Rounding Summaries for Families of Critically Ill Patients
NCT03969810
Pulmonary Infections and Barotrauma Associated With MV IN PICU
NCT05792501
Parent-to-parent Coaching While Awaiting Hospital Discharge With a Child With a Ventilator
NCT05880953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Professional interpretation has been shown to mitigate negative outcomes for this population. For instance, one study showed decreased mortality in the pediatric intensive care unit (PICU) for Latino patients after in-person interpreter availability was increased; however, interpreters are still widely underutilized. One study in a PICU revealed that only 53% of doctors and 41% of nurses used an interpreter "often" for their patients who needed it. To improve clinical outcomes for this population, communication with patients with LEP needs to be improved.
Health disparities as a result of limited English proficiency are unjust, and a just medical system would allow patients with LEP to access the same quality of care as their English-proficiency counterparts. One way to improve communication may be to provide families with an opportunity to initiate interpreter use on their own. Although families have expressed a desire for this, no previous studies have examined the effects of this strategy.
Hypothesis:
The study team hypothesizes that implementing a novel family-initiated interpretation system will lead to greater use of interpreters, compared to the current standard of care. The investigators plan to test this hypothesis in the PICU. The specific aims are:
Explore the feasibility, usability, and acceptability of a family-initiated interpreter intervention among healthcare providers, and the acceptability of the intervention among families with limited English proficiency.
Examine the impact of family-initiated interpretation intervention on professional interpreter utilization by comparing pre and post-intervention professional interpreter utilization rates in the PICU.
By allowing families to initiate contact with an interpreter, the study team believe that interpreter utilization will increase, with the potential to decrease disparities in the limited English proficiency population. This work will inform future work to improve care for patients with limited English proficiency, and the investigators plan to investigate the clinical impact of this interpreter modality in future projects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pre-Intervention
The medical team will use standard interpreter practices with this group.
No interventions assigned to this group
Interventional
This arm will be given interpreter tablets in order to allow them to call interpreter themselves.
Family Initiated Interpretation
Interpreter tablet will be given to families so they can contact an interpreter themselves.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Family Initiated Interpretation
Interpreter tablet will be given to families so they can contact an interpreter themselves.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northwestern University Feinberg School of Medicine
OTHER
Ann & Robert H Lurie Children's Hospital of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mary Pilarz, MD
Role: PRINCIPAL_INVESTIGATOR
Ann and Robert H. Lurie Children's Hospital of Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-5221
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.